157 results
Page 3 of 8
424B5
uvsf4n
17 Feb 21
Prospectus supplement for primary offering
12:00am
424B5
t1492qu5ebcek 1gwp1
11 Feb 21
Prospectus supplement for primary offering
5:28pm
8-K
EX-10.1
93zv04d i33z
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
424B2
v2ihsad15jxg2otlq
2 Oct 20
Prospectus for primary offering
4:16pm
8-K
EX-10.1
okrldalun
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
EX-10.2
afh9k
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
424B3
4dyk1f66
8 Jun 20
Prospectus supplement
4:48pm
8-K
EX-10.2
kfbp 1hj88un3
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-4.1
b043yjgm3vpaid
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-10.1
dvsh75s7v1erx3b4
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
424B5
81md0
19 May 20
Prospectus supplement for primary offering
5:29pm
8-K
EX-4.2
we3kbl6
8 May 20
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
4:40pm
8-K
EX-4.1
odr u7sxubyv
8 May 20
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
4:40pm